EGFR and neoplasm: Here, we retrospectively analyzed the tumor proportion score (TPS) for PD-L1 expression and CD8+ TILs in paired tumor tissues from NSCLC patients harboring activating EGFR mutants before and after developing acquired resistance to EGFR-TKIs.